Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability
- 15 February 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (4), 424-428
- https://doi.org/10.1021/acsmedchemlett.6b00009
Abstract
Cannabidiol is the nonpsychoactive natural component of C. sativa that has been shown to be neuroprotective in multiple animal models. Our interest is to advance a therapeutic candidate for the orphan indication hepatic encephalopathy (HE). HE is a serious neurological disorder that occurs in patients with cirrhosis or liver failure. Although cannabidiol is effective in models of HE, it has limitations in terms of safety and oral bioavailability. Herein, we describe a series of side chain modified resorcinols that were designed for greater hydrophilicity and “drug likeness”, while varying hydrogen bond donors, acceptors, architecture, basicity, neutrality, acidity, and polar surface area within the pendent group. Our primary screen evaluated the ability of the test agents to prevent damage to hippocampal neurons induced by ammonium acetate and ethanol at clinically relevant concentrations. Notably, KLS-13019 was 50-fold more potent and >400-fold safer than cannabidiol and exhibited an in vitro profile consistent with improved oral bioavailability.Keywords
This publication has 20 references indexed in Scilit:
- Mapping Metabolic Brain Activity in Three Models of Hepatic EncephalopathyInternational Journal of Hypertension, 2013
- Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomesLife Sciences, 2011
- Cannabidiol improves brain and liver function in a fulminant hepatic failure‐induced model of hepatic encephalopathy in miceBritish Journal of Pharmacology, 2010
- Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic StrokePharmaceuticals, 2010
- Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+LevelsJournal of Neuroscience, 2009
- C1‘-Cycloalkyl Side Chain Pharmacophore in TetrahydrocannabinolsJournal of Medicinal Chemistry, 2007
- Structure−Brain Exposure RelationshipsJournal of Medicinal Chemistry, 2006
- New Cannabidiol Derivatives: Synthesis, Binding to Cannabinoid Receptor, and Evaluation of Their Antiinflammatory ActivityJournal of Medicinal Chemistry, 2006
- Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamideBritish Journal of Pharmacology, 2001
- Acute and chronic ethanol increases reactive oxygen species generation and decreases viability in fresh, isolated rat hepatocytesHepatology, 1998